Skip to content

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

Comparison of Glycaemic Fluctuations During 3 Days Subcutaneous Continuous Monitoring in Patients With Basal Substitution Human Insulin NPH vs Insuline Glargine

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00322075
Enrollment
35
Registered
2006-05-04
Start date
2006-04-30
Completion date
2006-11-30
Last updated
2007-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Comparison of incidence of hypoglycaemic events and glycaemic fluctuations in diabetic patients with basal substitution with NPH insuline versus insuline glargine. Evaluation of HbA1c, FBG (Fasting Blood Glucose), BMI (Body Mass Index), dose of insulin, ratio of basal and prandial insulin, satisfaction with treatment, incidence of adverse events.

Interventions

DRUGinsulin glargine

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients with Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2 with HbA1c 6% and more with more than 2 confirmed hypoglycaemic events (glycaemia less than 3,3 mmol/l) during last year

Exclusion criteria

* Diabetic ketoacidosis * Any other severe disease * Pregnancy or fertile female without contraception * Alcohol/drug abuse, selected prohibited concomitant medication * Nightshift work

Design outcomes

Primary

MeasureTime frame
3 days continual glycaemic profile fluctuation
occurrence of adverse events
HbA1c
FBG
BMI
total daily dose of insulin and ratio of doses of basal/prandial insulines
patients´satisfaction

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026